Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Viale

Showing results (251-260 of 302) with videos related to

Pageof 31
Sort By:
British Journal of Cancer|April 13, 2013
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotypeM Lazzeroni, A Guerrieri-Gonzaga, E Botteri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2012
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group StatementS Guiu, S Michiels, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapyJ H Park, S F Jonas, G Bataillon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trialG Viale, L Slaets, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational studyA Guerrieri-Gonzaga, E Botteri, M Lazzeroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2008
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 TrialB C Pestalozzi, P Francis, E Quinaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2020
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 studyS J Luen, R Asher, C K Lee, et al.
Breast Cancer Research and Treatment|April 1, 2011
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypesG Cancello, P Maisonneuve, N Rotmensz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2024
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners FoundationS Peters, S Loi, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Pageof 31

Showing results (251-260 of 302) with videos related to

Sort By:
Pageof 31
British Journal of Cancer|April 13, 2013
Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotypeM Lazzeroni, A Guerrieri-Gonzaga, E Botteri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2012
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group StatementS Guiu, S Michiels, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2019
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapyJ H Park, S F Jonas, G Bataillon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trialG Viale, L Slaets, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2009
Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational studyA Guerrieri-Gonzaga, E Botteri, M Lazzeroni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2008
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 TrialB C Pestalozzi, P Francis, E Quinaux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2020
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 studyS J Luen, R Asher, C K Lee, et al.
Breast Cancer Research and Treatment|April 1, 2011
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypesG Cancello, P Maisonneuve, N Rotmensz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 22, 2024
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners FoundationS Peters, S Loi, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Pageof 31